Gyre Therapeutics (L9S) AI Stock Analysis

1 Followers

Gyre Therapeutics

(Frankfurt:L9S)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue Growth and Gross MarginRapid revenue expansion combined with exceptionally high, stable gross margins indicates strong commercial economics and meaningful product value. If maintained, this profile can support reinvestment in development, strengthen operating leverage, and provide a durable base for future profitability.

Negative Factors

Persistent Cash BurnDeeply negative operating and free cash flow show that current activities are consuming substantial cash despite revenue growth. If sustained, this can constrain internal funding for clinical development and increase reliance on financing or operating improvements to maintain strategic flexibility.

Gyre Therapeutics (L9S) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 451.70M
Dividend Yield: ―
Average Volume (3M): 92
Price to Earnings (P/E): -15.3
Beta (1Y): 0.91
Revenue Growth: 8.26%
EPS Growth: -443.88%
Country: Germany
Employees: 625
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenid...

Gyre Therapeutics Risk Analysis

Gyre Therapeutics disclosed 98 risk factors in its most recent earnings report. Gyre Therapeutics reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Our common stock is thinly traded and our outstanding shares are concentrated among a small number of holders. Sales of a substantial number of shares of our common stock, including in connection with the expiration of contractual lock-up agreements or any foreclosure upon shares pledged by our controlling stockholder, or the perception that such sales could occur, could cause the market price of our common stock to decline significantly.Q2, 2026

Gyre Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:L9S against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SGMT	55Neutral	$766.02M	-8.91	-31.96%	―	―	30.54%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IVA	48Neutral	$891.48M	-6.61	-1625.48%	―	-99.61%	66.37%
GALT	44Neutral	$340.87M	-7.70	21.48%	―	―	33.25%

* Healthcare Sector Average

Performance Comparison

DE:L9S and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:L9S	Gyre Therapeutics Inc	4.12	-3.03	-42.38%
GALT	Galectin Therapeutics (GALT)	3.29	-2.24	-40.51%
IVA	Inventiva SA ADR	4.01	0.19	4.97%
SGMT	Sagimet Biosciences, Inc. Class A	11.41	3.67	47.42%
AVLN	Avalyn Pharma Inc	31.62	2.13	7.22%
VCRE	Vicore Pharma Holding AB Sponsored ADR	11.31	-2.15	-15.99%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Gyre Therapeutics AI Stock Analysis